Human immunodeficiency virus (HIV) type 1 infection status and in vitro susceptibility to HIV infection among high-risk HIV-1-seronegative hemophiliacs.
Blood samples were obtained from 16 hemophiliacs who had a 50%-94% defined risk of human immunodeficiency virus (HIV) type 1 infection on the basis of treatment history and from 14 controls not at risk for HIV infection. HIV-1 was not detected in any of 12 patient samples by cocultivation nor in 14 patient samples by the polymerase chain reaction. Peripheral blood cells from 7 seronegative hemophiliacs at highest risk of seroconversion (94%) were less susceptible to HIV-1 infection in vitro than were cells from healthy controls (P < .025, one-tailed Wilcoxon rank sum test). In contrast, the susceptibility to HIV-1 infection of lymphocytes from 6 seronegative hemophiliacs at moderate risk (50%-56%) of seroconversion did not differ from that of cells from controls or from high-risk hemophiliacs. Therefore, prolonged periods of seronegative HIV-1 infection are not common in this high-risk population. In addition, among hemophiliacs there may exist heterogeneity in susceptibility to HIV-1 infection in vitro and in vivo.
Lederman
M M
MM
Case Western Reserve University School of Medicine, Ohio, USA.
Jackson
J B
JB
Kroner
B L
BL
White
G C
GC
Eyster
M E
ME
Aledort
L M
LM
Hilgartner
M W
MW
Kessler
C M
CM
Cohen
A R
AR
Kiger
K P
KP
D000328:Adult; D018791:CD4 Lymphocyte Count; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D004198:Disease Susceptibility; D005164:Factor IX / Q000032:analysis; D005169:Factor VIII / Q000032:analysis; D015658:HIV Infections / Q000453:epidemiology* / Q000635:transmission; D018023:HIV Seronegativity; D006679:HIV Seropositivity / Q000276:immunology*; D015497:HIV-1 / Q000235:genetics / Q000302:isolation & purification; D006467:Hemophilia A / Q000097:blood / Q000150:complications* / Q000276:immunology; D006801:Humans; D018655:Lymphocyte Count; D008297:Male; D016133:Polymerase Chain Reaction; D012307:Risk Factors
D005169:Factor VIII; D005164:Factor IX